Premium
Serum magnesium concentration is inversely associated with fibroblast growth factor 23 in haemodialysis patients
Author(s) -
Iguchi Akira,
Watanabe Yasuo,
Iino Noriaki,
Kazama Junichiro James,
Iesato Hiroshi,
Narita Ichiei
Publication year - 2014
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12287
Subject(s) - fibroblast growth factor 23 , magnesium , medicine , endocrinology , fibroblast , growth factor , parathyroid hormone , fibroblast growth factor , kidney disease , calcium , chemistry , biochemistry , receptor , in vitro , organic chemistry
Aim Fibroblast growth factor 23 is reported to be a pivotal regulator for the chronic kidney disease‐mineral bone disorders, working in coordinated ways with phosphate, calcium, and parathyroid hormone. However, whether there is a relationship between fibroblast growth factor 23 and magnesium is currently unclear. To address this, we performed a cross‐sectional observational study in haemodialysis patients. Methods We measured the serum levels of fibroblast growth factor 23, magnesium and other factors that are implicated in chronic kidney disease‐mineral bone disorders in 225 haemodialysis patients. Results Simple correlation analysis showed that fibroblast growth factor 23 was not correlated with magnesium. However, upon multiple regression analysis, a significant negative correlation was found between fibroblast growth factor 23 and magunesium (b = −0.164, P = 0.0020). Moreover, the levels of fibroblast growth factor 23 in patients treated with magnesium oxide had significantly lower levels than those without magnesium oxide. Conclusion We speculate that the magnesium is a potential regulator of fibroblast growth factor 23 levels in haemodialysis patients. Our data suggest that follow‐up studies to elucidate the molecular mechanisms that underlie this relationship are warranted.